Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2372 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate whether there are genetic differences between patients with rheumatic heart disease and members of the general population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RhEumatiC Heart diseAse Genetics

NCT02118818

Rheumatic Heart Disease

COMPLETED

The Prevalence of Rheumatic Heart Disease in School Children in Fiji

NCT00779662

Rheumatic Heart Disease

UNKNOWN

The Genetic Basis of Acquired Heart Disease in Africa

NCT02124109

Rheumatic Heart Disease Rheumatic Fever Endomyocardial Fibrosis +1 more

COMPLETED

Genetic of Chronic Kidney Disease and Gout in New Caledonia

NCT05607797

Gout Renal Insufficiency, Chronic

COMPLETED NA

Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy

NCT06896266

Arrhythmia Cardiomyopathy Arrhythmia-induced Cardiomyopathy (AiCM)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will micro-array genotype approximately 300,000 single nucleotide polymorphisms (SNP) using DNA samples from patients with rheumatic heart disease (cases) from New Caledonia and Fiji, and members of the general population (controls) from New Caledonia, Vanuatu and Fiji. The investigators will perform standard quality control checks on the SNP data using measures such as call rate, heterozygosity, duplication and relatedness, and exclude variants on the basis of deviation from Hardy-Weinberg equilibrium and minor allele frequency. We will also impute variants not present on the micro-array with reference to the latest release of 1000 Genomes data and whole-genome sequence data from sixty Melanesian individuals from New Caledonia from the phenotypic extremes in this study.

The investigators will conduct a discovery analysis in using a genome-wide association study approach focusing on Oceanic cases and controls from the Francophone nations of New Caledonia and Vanuatu. This analysis will be corrected for bias due to population stratification using the Linear Mixed Model (LMM) and consider additive, dominant and recessive genetic models. The investigators will then perform LMM association testing for variants with P-value in the discovery analysis less than 1x10\^-5 in Oceanic cases and controls from Fiji and combine the association statistics by fixed-effects meta-analysis. The investigators will consider variants with significant effects in the same direction in discovery and replication analyses with combined P-value less than 1x10\^-8 to have replicated. Unless there is clear evidence that associated variants are specific to Oceanic populations, further replication analyses for associated variants in cases and controls of Indian Descent from Fiji, as well as individuals of other and admixed ethnicities from both Fiji and New Caledonia.

Recruitment completed in December 2013. After receipt of funding from the British Heart Foundation, genotyping and analysis will begin in July 2014.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatic Heart Disease Mitral Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rheumatic heart disease cases

Patients with rheumatic heart disease as defined in the case criteria

No interventions assigned to this group

Population controls

Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of rheumatic heart disease based on one of:

* World Heart Federation definite echocardiographic criteria
* World Heart Federation borderline echocardiographic criteria and history of acute rheumatic fever
* Mitral stenosis with valve area less than 2.0 cm2
* Previous surgery for rheumatic heart disease

* Healthy individual living in a community where cases were identified

Exclusion Criteria

* Age less than five years
* Inability to give consent
2. New Controls

* Past medical history or systems suggestive of rheumatic heart disease, acute rheumatic fever or other valvular heart disease
* Age less than five years
* Inability to give consent

Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes